Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| SELLAS Life Sciences Group Inc. | Galinpepimut-S - (REGAL) | Acute Myeloid Leukemia (AML) | Phase 3 | Type Meeting | Intravenous | Oncology |
| SELLAS Life Sciences Group Inc. | NPS (Nelipepimut-S) and HERCEPTIN (Trastuzumab) | HER2 3+ breast cancer | Phase 2b | Trial Discontinued | Intravenous | Oncology |
| SELLAS Life Sciences Group Inc. | Tambiciclib (SLS009) (GFH009) with venetoclax | Hematologic malignancies, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and lymphoma | Phase 2 | Data Released | Intravenous | Oncology |
| SELLAS Life Sciences Group Inc. | SLS009 (tambiciclib) with zanubrutinib | relapsed/refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) | Phase 2a | Data Released | oral | Oncology |
| Seres Therapeutics Inc. | SER-287 - (ECO-RESET) | Mild-to-Moderate Ulcerative Colitis | Phase 2b | Trial Discontinued | Oral | Gastroenterology |
| Seres Therapeutics Inc. | SER-155 | Gastrointestinal infections, bacteremia and graft versus host disease (GvHD) | Phase 2 | Ongoing | Oral | Immunosuppressant |
| Seres Therapeutics Inc. | SER-301 | Ulcerative Colitis | Phase 2 | Ongoing | oral | Gastroenterology |
| Seres Therapeutics Inc. | SER-301 | Ulcerative Colitis | Phase 2 | Ongoing | oral | Gastroenterology |
